BioSpace News Archive

ANAVEX ® 2-73 treatment resulted in significant increase in the expression of the SIGMAR1 mRNA biomarker that significantly correlated with improvements in the primary and secondary clinical efficacy endpoints CoA (p = 0.029) and MDS-UPDRS Part III (p = 0.024) and MDS-UPDRS Total (p = 0.038) 14.51-point MDS-UPDRS (Movement Disorder Society- Unified Parkinson Disease Rating Scale) Total score improvement compared to placebo (p = 0.034) Data strengthens regulatory pathway for Parkinson’s d

Bio-Techne Corporation announced the opening of its new Ireland facility located in Dublin.

MSL Solutions. Designed to grow and enhance both organizations’ ability to deliver world-class MSL services to pharma’s Medical Affairs function, the new offering blends Envision’s and Two Labs’ capabilities.

XSOLIS, a healthcare technology firm focused on improving healthcare operations, today announced that it has secured a $75 million minority growth investment from Brighton Park Capital.

Crescita Therapeutics Announces 9-Country Licensing Agreement with Croma Pharma for Pliaglis.

The growing prevalence of coronary artery diseases stands as a key factor aiding in expansion of the global antisense and RNAi therapeutics market and is likely to continue so during the forecast period set between 2020 and 2030.

There has been augmented focus on personalized medicines and drug discovery utilizing in vitro methods.

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug Application for ORIC-533 to proceed into a first-in-human clinical trial.

180 Life Sciences Corp. announced that as previously disclosed in the Current Report on Form 8-K, filed by 180 Life Sciences Corp. with the SEC on April 19, 2021, on April 16, 2021, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market, LLC stating that the Company was not in compliance with Nasdaq Listing Rule 5250 because it had not yet filed its Annual Report on Form 10-K for the year ended December 31, 2020 with the Commission.

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced it has been added to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes effective after the U.S. markets open , June 28, 2021, as part of the 2021 Russell US Indexes Reconstitution.